Cargando…

A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification

PURPOSE: Hepatocellular carcinoma (HCC) is a kind of primary liver cancer. It is a common malignant tumor of digestive system that is difficult to predict the prognosis of patients. As an important epigenetic modification, N7 methyl guanosine (m7G) is indispensable in gene regulation. This regulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li, Wang, Yi-ran, Mou, Zhi-qiang, Xiong, Ping-fu, Deng, Kun, Wen, Jian, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120187/
https://www.ncbi.nlm.nih.gov/pubmed/37081394
http://dx.doi.org/10.1186/s12876-023-02757-9
_version_ 1785029143721672704
author Yang, Li
Wang, Yi-ran
Mou, Zhi-qiang
Xiong, Ping-fu
Deng, Kun
Wen, Jian
Li, Jing
author_facet Yang, Li
Wang, Yi-ran
Mou, Zhi-qiang
Xiong, Ping-fu
Deng, Kun
Wen, Jian
Li, Jing
author_sort Yang, Li
collection PubMed
description PURPOSE: Hepatocellular carcinoma (HCC) is a kind of primary liver cancer. It is a common malignant tumor of digestive system that is difficult to predict the prognosis of patients. As an important epigenetic modification, N7 methyl guanosine (m7G) is indispensable in gene regulation. This regulation may affect the development and occurrence of cancer. However, the prognosis of long non coding RNAs (lncRNAs) in HCC is limited, especially how m7G-related lncRNAs regulate the development of HCC has not been reported. METHODS: The Cancer Genome Atlas (TCGA) provides us with the expression data and corresponding clinical information of HCC patients we need. We used a series of statistical methods to screen four kinds of m7G-related lncRNAs related to HCC prognosis and through a series of verifications, the results were in line with our expectations. Finally, we also explored the IC50 difference and correlation analysis of various common chemotherapy drugs. RESULT: Our study identified four differentially expressed m7g-related lncRNAs associated with HCC prognosis. Survival curve analysis showed that high risk lncRNAs would lead to poor prognosis of HCC patients. M7G signature's AUC was 0.789, which shows that the prognosis model we studied has certain significance in predicting the prognosis of HCC patients. Moreover, our study found that different risk groups have different immune and tumor related pathways through gene set enrichment analysis. In addition, many immune cell functions are significantly different among different risk groups, such as T cell functions, including coordination of type I INF response and coordination of type II INF response. The expression of PDCD1, HHLA2, CTLA-4 and many other immune checkpoints in different risk groups is also different. Additionally, we analyzed the differences of IC50 and risk correlation of 15 chemotherapeutic drugs among different risk groups. CONCLUSION: A novel lncRNAs associated with m7G predicts the prognosis of HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02757-9.
format Online
Article
Text
id pubmed-10120187
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101201872023-04-22 A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification Yang, Li Wang, Yi-ran Mou, Zhi-qiang Xiong, Ping-fu Deng, Kun Wen, Jian Li, Jing BMC Gastroenterol Research PURPOSE: Hepatocellular carcinoma (HCC) is a kind of primary liver cancer. It is a common malignant tumor of digestive system that is difficult to predict the prognosis of patients. As an important epigenetic modification, N7 methyl guanosine (m7G) is indispensable in gene regulation. This regulation may affect the development and occurrence of cancer. However, the prognosis of long non coding RNAs (lncRNAs) in HCC is limited, especially how m7G-related lncRNAs regulate the development of HCC has not been reported. METHODS: The Cancer Genome Atlas (TCGA) provides us with the expression data and corresponding clinical information of HCC patients we need. We used a series of statistical methods to screen four kinds of m7G-related lncRNAs related to HCC prognosis and through a series of verifications, the results were in line with our expectations. Finally, we also explored the IC50 difference and correlation analysis of various common chemotherapy drugs. RESULT: Our study identified four differentially expressed m7g-related lncRNAs associated with HCC prognosis. Survival curve analysis showed that high risk lncRNAs would lead to poor prognosis of HCC patients. M7G signature's AUC was 0.789, which shows that the prognosis model we studied has certain significance in predicting the prognosis of HCC patients. Moreover, our study found that different risk groups have different immune and tumor related pathways through gene set enrichment analysis. In addition, many immune cell functions are significantly different among different risk groups, such as T cell functions, including coordination of type I INF response and coordination of type II INF response. The expression of PDCD1, HHLA2, CTLA-4 and many other immune checkpoints in different risk groups is also different. Additionally, we analyzed the differences of IC50 and risk correlation of 15 chemotherapeutic drugs among different risk groups. CONCLUSION: A novel lncRNAs associated with m7G predicts the prognosis of HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02757-9. BioMed Central 2023-04-20 /pmc/articles/PMC10120187/ /pubmed/37081394 http://dx.doi.org/10.1186/s12876-023-02757-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Li
Wang, Yi-ran
Mou, Zhi-qiang
Xiong, Ping-fu
Deng, Kun
Wen, Jian
Li, Jing
A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
title A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
title_full A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
title_fullStr A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
title_full_unstemmed A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
title_short A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
title_sort new prediction model of hepatocellular carcinoma based on n7-methylguanosine modification
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120187/
https://www.ncbi.nlm.nih.gov/pubmed/37081394
http://dx.doi.org/10.1186/s12876-023-02757-9
work_keys_str_mv AT yangli anewpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT wangyiran anewpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT mouzhiqiang anewpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT xiongpingfu anewpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT dengkun anewpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT wenjian anewpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT lijing anewpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT yangli newpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT wangyiran newpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT mouzhiqiang newpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT xiongpingfu newpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT dengkun newpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT wenjian newpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification
AT lijing newpredictionmodelofhepatocellularcarcinomabasedonn7methylguanosinemodification